MAIN ARTICLE
An established treatment exits the market
Premarin contains conjugated estrogens and has been prescribed for symptoms linked to falling estrogen levels, including vaginal dryness and painful intercourse after menopause. Canadian supplies of the vaginal cream had been disrupted for months before Pfizer confirmed that it would stop selling the product. For affected patients, the announcement formalizes a problem they may already have encountered when attempting to fill a prescription.
Pfizer expects inventories of the 0.3-milligram, 0.625-milligram and 1.25-milligram oral tablets to last until around the middle of 2027. That is a projection, not a guarantee that every pharmacy or region will retain every strength. Demand can shift quickly after a discontinuation announcement, especially when patients and prescribers begin looking for a stable supply.
The company has stressed that the Canadian withdrawal is not connected to fresh safety, efficacy or quality findings. The decision does not affect Premarin Intravenous, a distinct hospital product used for certain cases of abnormal uterine bleeding. Keeping those distinctions clear matters: discontinuing sales is not synonymous with recalling a treatment for newly discovered harm.














